A citation-based method for searching scientific literature

Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E Hawkes, Christine Huppertz, Torsten Kuiper, Iain B McInnes, Christopher T Ritchlin, David Rosmarin, Georg Schett, José M Carballido, Peter Häusermann, Claudio Calonder, Beate Vogel, Jean-Michel Rondeau, Gerard Bruin. Pharmacol Ther 2022
Times Cited: 5







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
60

Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.
Harumichi Ishigame, Shigeru Kakuta, Takeshi Nagai, Motohiko Kadoki, Aya Nambu, Yutaka Komiyama, Noriyuki Fujikado, Yuko Tanahashi, Aoi Akitsu, Hayato Kotaki,[...]. Immunity 2009
726
40

Functional specialization of interleukin-17 family members.
Yoichiro Iwakura, Harumichi Ishigame, Shinobu Saijo, Susumu Nakae. Immunity 2011
858
40

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
Heon Park, Zhaoxia Li, Xuexian O Yang, Seon Hee Chang, Roza Nurieva, Yi-Hong Wang, Ying Wang, Leroy Hood, Zhou Zhu, Qiang Tian,[...]. Nat Immunol 2005
40

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
Gerard Bruin, Christian Loesche, Judit Nyirady, Oliver Sander. J Clin Pharmacol 2017
31
20

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.
Paul A Harris, Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, Jose G Conde. J Biomed Inform 2009
20

Assessing response and loss of response to biological therapies in IBD.
Henit Yanai, Stephen B Hanauer. Am J Gastroenterol 2011
241
20

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
Alexander Egeberg, Lars Erik Bryld, Lone Skov. J Am Acad Dermatol 2019
43
20

pROC: an open-source package for R and S+ to analyze and compare ROC curves.
Xavier Robin, Natacha Turck, Alexandre Hainard, Natalia Tiberti, Frédérique Lisacek, Jean-Charles Sanchez, Markus Müller. BMC Bioinformatics 2011
20

No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Therezia Bokor-Billmann, Knut Schäkel. J Dermatolog Treat 2019
17
20

Stability of selected serum proteins after long-term storage in the Janus Serum Bank.
Randi E Gislefoss, Tom K Grimsrud, Lars Mørkrid. Clin Chem Lab Med 2009
79
20

Cause-specific mortality in patients with psoriasis and psoriatic arthritis.
L Skov, S F Thomsen, L E Kristensen, R Dodge, M S Hedegaard, J Kjellberg. Br J Dermatol 2019
21
20

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays.
Sumin Bian, Thomas Van Stappen, Filip Baert, Griet Compernolle, Els Brouwers, Sophie Tops, Annick de Vries, Theo Rispens, Jeroen Lammertyn, Séverine Vermeire,[...]. J Pharm Biomed Anal 2016
26
20

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
K Reich, L Puig, J C Szepietowski, C Paul, J P Lacour, A Tsianakas, C Sieder, M Rissler, E Pournara, R Orsenigo. Br J Dermatol 2020
25
20

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
Jillian Frieder, Dario Kivelevitch, Alan Menter. Ther Adv Chronic Dis 2018
88
20

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.
Erwin Dreesen, Peter Bossuyt, Denis Mulleman, Ann Gils, Dora Pascual-Salcedo. Clin Pharmacol 2017
39
20

The REDCap consortium: Building an international community of software platform partners.
Paul A Harris, Robert Taylor, Brenda L Minor, Veida Elliott, Michelle Fernandez, Lindsay O'Neal, Laura McLeod, Giovanni Delacqua, Francesco Delacqua, Jacqueline Kirby,[...]. J Biomed Inform 2019
20

Assessment of actual significance levels for covariate effects in NONMEM.
U Wählby, E N Jonsson, M O Karlsson. J Pharmacokinet Pharmacodyn 2001
238
20


Psoriasis comorbidities: complications and benefits of immunobiological treatment.
André Vicente Esteves de Carvalho, Ricardo Romiti, Cacilda da Silva Souza, Renato Soriani Paschoal, Laura de Mattos Milman, Luana Pizarro Meneghello. An Bras Dermatol 2016
21
20

Stopping Biologics in IBD-What Is the Evidence?
Edouard Louis. Inflamm Bowel Dis 2018
16
20

Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study.
Jorge R Georgakopoulos, Arvin Ighani, Michelle Phung, Jensen Yeung. J Am Acad Dermatol 2018
33
20

Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
O Baniandrés, V J Rodríguez-Soria, R M Romero-Jiménez, R Suárez. Actas Dermosifiliogr 2015
19
20

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.
Evelien Moorkens, Clara Jonker-Exler, Isabelle Huys, Paul Declerck, Steven Simoens, Arnold G Vulto. Front Pharmacol 2016
54
20

Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
Wannee Kantasiripitak, Ruth Van Daele, Matthias Gijsen, Marc Ferrante, Isabel Spriet, Erwin Dreesen. Front Pharmacol 2020
41
20

Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy.
Rani Soenen, Evelyn Meulewaeter, Lynda Grine, Nathalie Van den Berghe, Els Brouwers, Reinhart Speeckaert, Sven Lanssens, Linda Temmerman, Jo Lambert, Ann Gils. J Invest Dermatol 2019
9
20

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
K Reich, A Blauvelt, A Armstrong, R G Langley, A de Vera, F Kolbinger, S Spindeldreher, M Ren, G Bruin. J Eur Acad Dermatol Venereol 2019
14
20


Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
Konstantinos Papamichael, Erik H Vogelzang, Jo Lambert, Gertjan Wolbink, Adam S Cheifetz. Expert Rev Clin Immunol 2019
40
20

Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study.
M Esposito, P Gisondi, A Conti, A Giunta, M Del Giglio, M Di Mercurio, L Veneziano, G Ferrucci, L Bianchi, S Chimenti,[...]. J Eur Acad Dermatol Venereol 2017
21
20

Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data.
Jerry Bagel, Brad Glick, Jashin J Wu, Ishveen Chopra, Xue Song, Matthew Brouillette, Alan Mendelsohn, Stephen Rozzo, George Han. J Med Econ 2021
2
50

Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis.
Michelle Phung, Arvin Ighani, Jorge R Georgakopoulos, Ron Vender, Lyne Giroux, Perla Lansang, Jensen Yeung. J Cutan Med Surg 2019
8
20

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
R Bissonnette, T Luger, D Thaçi, D Toth, A Lacombe, S Xia, R Mazur, M Patekar, P Charef, M Milutinovic,[...]. J Eur Acad Dermatol Venereol 2018
123
20

Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment.
Ji S van Bezooijen, Marco W J Schreurs, Birgit C P Koch, Henk Te Velthuis, Martijn B A van Doorn, Errol P Prens, Teun van Gelder. Ther Drug Monit 2017
3
33

Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Jashin J Wu, Steven R Feldman, Shipra Rastogi, Brandy Menges, Melissa Lingohr-Smith, Jay Lin. J Dermatolog Treat 2018
23
20

The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
Lisa Lynn Ten Bergen, Aleksandra Petrovic, Anders Krogh Aarebrot, Silke Appel. Scand J Immunol 2020
19
20

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.
Juul M P A van den Reek, Lieke J van Vugt, Martijn B A van Doorn, Gayle E van der Kraaij, Wim J A de Kort, Georges P H Lucker, Barbara Horvath, M David Njoo, H Jorn Bovenschen, Paul M Ossenkoppele,[...]. Acta Derm Venereol 2018
44
20

Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Konstantinos Papamichael, Adam S Cheifetz. Curr Opin Rheumatol 2020
10
20

Continued treatment with secukinumab is associated with high retention or regain of response.
M Augustin, D Thaci, K Eyerich, A Pinter, M Radtke, F Lauffer, U Mrowietz, S Gerdes, D Pariser, M Lebwohl,[...]. Br J Dermatol 2020
6
20


Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series.
Michelle Phung, Jorge R Georgakopoulos, Arvin Ighani, Lyne Giroux, Jensen Yeung. JAAD Case Rep 2018
13
20

Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
K Reich, A Körber, U Mrowietz, M Sticherling, C Sieder, J Früh, T Bachhuber. Br J Dermatol 2021
9
20




Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
Mark Lebwohl, Newman Yeilding, Philippe Szapary, Yuhua Wang, Shu Li, Yaowei Zhu, Kristian Reich, Richard G Langley, Kim A Papp. J Am Acad Dermatol 2010
89
20

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks.
Yuan Yu Michael Huang, Jennifer Shuley Ruth, Sylvia Hsu. J Am Acad Dermatol 2016
18
20

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.
Selma Atalay, Juul M P A van den Reek, Marisol E Otero, Marcellus D Njoo, Johannes M Mommers, Paul M Ossenkoppele, Marjolein I Koetsier, Maartje M Berends, Peter C M van de Kerkhof, Hans M M Groenewoud,[...]. Acta Derm Venereol 2020
6
20

Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Thomas Van Stappen, Els Brouwers, Sophie Tops, Nick Geukens, Séverine Vermeire, Paul J Declerck, Ann Gils. Ther Drug Monit 2015
35
20

The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity.
Wolf-Henning Boehncke, Sandra Boehncke, Anne-Marie Tobin, Brian Kirby. Exp Dermatol 2011
314
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.